Grupo Ageas Portugal Selects FRISS To Prevent and Protect Their Customers From Fraud
Grupo Ageas Portugal, serving approximately 1.7 million clients with 1,281 employees and via 2,722 agents, announced today that they have selected FRISS Fraud Detection at Claims in order to streamline their digital claim handling and prevent and protect their customers from fraud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005826/en/
By selecting FRISS, Grupo Ageas Portugal will further drive its digital transformation and safely streamline operations. (Graphic: Business Wire)
The real-time FRISS solution provides a unique combination of out-of-the-box risk and fraud indicators with powerful AI techniques such as predictive models, network analysis, and text mining. With this flexible and future-proof claims fraud solution, Grupo Ageas Portugal will further drive its digital transformation and safely streamline operations. Its customers can be helped with service beyond insurance, while high risks will be automatically flagged for further investigation.
The FRISS solution is pre-integrated with Duck Creek Claims. In order to provide a seamless experience for their claim adjusters, Grupo Ageas Portugal will be using the Anywhere Enabled Integration for this solution available in Duck Creek’s Content Exchange. Besides delivering fast customer service for the insurer’s clients, this will also limit the amount of false positives, giving employees time to focus on their customers. This is a great example of a technology-driven partnership in innovation.
Sjoerd Smeets, Chief Risk Officer at Grupo Ageas, said: "With the choice of FRISS, we have opted for a company fully dedicated to fraud prevention. During the selection process, they have shown their industry knowledge, good technical solutions, and especially agility. We are confident that with FRISS we will detect more fraud, handle claims faster, and provide higher quality for our customers."
Ariane Braam-Verkoren, Global Alliance Manager at FRISS, added, “In my journey at FRISS to expand our business to many new territories in the world, I’m excited to see so many insurers join our quest for honest insurance. We are proud to have Grupo Ageas on board and to be their partner of choice in the fight against fraud in Portugal.”
“To offer the best in risk and fraud detection to our customers, it was critical for us to align with a partner like FRISS,” said Juan Antonio Costa, Country Manager for Spain & Portugal at Duck Creek Technologies. “Their solution employs ultra-modern technologies like machine learning and AI, and Grupo Ageas Portugal made an excellent choice for their customers and for the efficiency of their organization by rapidly executing this step in their digital transformation.”
FRISS Fraud Detection at Claims will be implemented at Grupo Ageas Portugal’s Motor, Property, WMC (Workers’ Compensation), and Personal Accidents lines of business.
About Grupo Ageas Portugal
Founded in 1824, Ageas is an international insurance group based in Brussels and present in 14 countries in Europe and Asia. Operating in Portugal since 2005, Ageas invests in the country as one of the main markets, where it intends to develop, through strong partnerships and contributing to the development of the country and society through the Ageas Foundation and helping Clients to manage, anticipate and protect yourself against risks and unforeseen circumstances, so that you can live the present and the future with maximum security and serenity. The Ageas Portugal Group's mission is to provide an emotional and relevant experience in people's lives, being a reference partner in insurance and the best workplace for entrepreneurial people. To this end, we have 1,281 Employees and 2,722 Mediators to provide an excellent service to the approximately 1.7 million Customers of the various commercial brands: Ageas Seguros, Ageas Pensões, Médis, Ocidental and Seguro Directo. In order to diversify the business and be close to its customers, the Ageas Portugal Group goes beyond insurance, offering a wide range of services through the Clínica Médis, Kleya, Go Far, Ageas Repara and Mundo Ageas. For more information, you can visit the website, or follow us on Linkedin and Instagram.
About Duck Creek Technologies:
Duck Creek Technologies is a leading provider of core system solutions to the P&C and General insurance industry. By accessing Duck Creek OnDemand, the company’s enterprise Software-as-a-Service solution, insurance carriers are able to navigate uncertainty and capture market opportunities faster than their competitors. Duck Creek’s functionally rich solutions are available on a stand-alone basis or as a full suite, and all are available via Duck Creek OnDemand. For more information, visit www.duckcreek.com.
FRISS is 100% focused on automated fraud and risk detection for P&C insurance companies worldwide. Their AI-powered detection solutions for underwriting, claims and SIU help 175+ insurers grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 4 months, realize up to 10 times ROI and 80% increase in straight through processing of policy application and claims. FRISS solutions help lower loss ratios, enable profitable portfolio growth, and improve the customer experience. For more information, please visit www.friss.com or Twitter.
For more information about this press release please contact:
Raúl Fernández Villota
FRISS Iberia Manager
+34 685 40 33 51
Ruud van Gerwen
FRISS Head of Global Marketing
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited1.12.2020 02:00:00 EET | Press release
Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (“Takeda”) in Asia Pacific, igniting efforts to strengthen its R&D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would acquire 18 "Primary Care" product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, "Celltrion Asia Pacific Pte, Ltd."1 ("Celltrion APAC"). Upon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia. The 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Eda
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific1.12.2020 02:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive of milestone payments. The portfolio includes 18 pharmaceutical products and over-the-counter (OTC) products sold in Asia Pacific, which is part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in June 2020. The divested portfolio includes pharmaceutical products and OTC products in the Cardiovascular, Diabetes and General Medicine therapeutic areas, sold in Australia, Hong Kong, Macau, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. The products, while addressing key patient needs in these countries and territories, are outside of the business areas Takeda has chosen as core to its global long-term growth. As part of the deal, Takeda will continue to manufacture the portfol
Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE®) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)1.12.2020 00:58:00 EET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a
Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group1.12.2020 00:00:00 EET | Press release
Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula
Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 19:45:00 EET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events
Emory University to Host a Live Webcast With His Holiness the Dalai Lama30.11.2020 18:39:00 EET | Press release
The Center for Contemplative Science and Compassion-Based Ethics at Emory University will host a live webinar with His Holiness the Dalai Lama on Tuesday, December 8, 2020. A discussion titled “The Necessity of Compassion for the Survival of Humanity” will feature the Dalai Lama in conversation with Melani A. Walton, co-founder of the Rob and Melani Walton Foundation, and Dr. Sanjay Gupta, chief medical correspondent for CNN. (For speaker photos click here.) The webcast begins at 10:30pm ET on Dec. 8, 2020 (Dec. 9 @ 9:00am India Standard Time) and will be simulcast in 14 languages. It is FREE of charge and open to anyone who’d like to participate. Advance registration is encouraged at https://compassionshift.emory.edu. “With so many urgent concerns impacting our world, the time is right to start a global conversation about the importance of compassion,” said Lobsang Tenzin Negi, executive director of Emory University’s Center for Contemplative Science and Compassion-Based Ethics. “For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom